ATE235915T1 - Behandlung von hämorrhagischem virusfieber mit protein c - Google Patents

Behandlung von hämorrhagischem virusfieber mit protein c

Info

Publication number
ATE235915T1
ATE235915T1 AT99965808T AT99965808T ATE235915T1 AT E235915 T1 ATE235915 T1 AT E235915T1 AT 99965808 T AT99965808 T AT 99965808T AT 99965808 T AT99965808 T AT 99965808T AT E235915 T1 ATE235915 T1 AT E235915T1
Authority
AT
Austria
Prior art keywords
protein
treatment
hemorrhagic virus
provides
virus fever
Prior art date
Application number
AT99965808T
Other languages
German (de)
English (en)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE235915T1 publication Critical patent/ATE235915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99965808T 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c ATE235915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (1)

Publication Number Publication Date
ATE235915T1 true ATE235915T1 (de) 2003-04-15

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965808T ATE235915T1 (de) 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c

Country Status (12)

Country Link
US (2) US6270764B1 (enExample)
EP (1) EP1131091B1 (enExample)
JP (1) JP2002530353A (enExample)
CN (1) CN1326356A (enExample)
AT (1) ATE235915T1 (enExample)
AU (1) AU2149800A (enExample)
BR (1) BR9915460A (enExample)
CA (1) CA2351470A1 (enExample)
DE (1) DE69906568T2 (enExample)
ES (1) ES2195655T3 (enExample)
IL (1) IL142220A0 (enExample)
WO (1) WO2000030677A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
BR0213293A (pt) 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
US20200093853A1 (en) * 2016-12-08 2020-03-26 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ZA983497B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインc誘導体

Also Published As

Publication number Publication date
ES2195655T3 (es) 2003-12-01
DE69906568T2 (de) 2004-02-12
US6767539B2 (en) 2004-07-27
DE69906568D1 (de) 2003-05-08
US20010028880A1 (en) 2001-10-11
CN1326356A (zh) 2001-12-12
CA2351470A1 (en) 2000-06-02
US6270764B1 (en) 2001-08-07
EP1131091A1 (en) 2001-09-12
WO2000030677A1 (en) 2000-06-02
IL142220A0 (en) 2002-03-10
AU2149800A (en) 2000-06-13
JP2002530353A (ja) 2002-09-17
BR9915460A (pt) 2001-07-17
EP1131091B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
ATE234092T1 (de) 2-alkylpyrrolidine
CA2232604A1 (fr) Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
DE69819360D1 (de) Neue psoralene zur inaktivierung von pathogenen
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
DE69916493D1 (de) Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
SE9404438D0 (sv) New process
IT9022507A0 (it) Procedimento per la preparazione di n-(26ammino63,5-dibromo-benzil)-trans-4-amminocicloesanolo3.
PT908107E (pt) Composicoes adocantes contendo neohesperidina-dihidrocalcona e pelo menos um outro adocante de elevada intensidade
FI954110L (fi) Menetelmä (1R,2R)-N-metyyli-2-(3-pyridyyli)-2-tetrahydrotiopyrankarbotiamodi-1-oksidin valmistamiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties